Eurofins Scientific, a global leader in biopharmaceutical product testing services, signed an exclusive agreement to acquire PHAST Gesellschaft für Pharmazeutische Qualitätsstandards mbH (PHAST), one of Europe’s leading service providers in the field of pharmaceutical products quality.
With more than 10 years of Good Manufacturing Practice (GMP) and Food and Drug Administration (FDA) compliance, PHAST serves the whole range of the biotech and pharma industry with a strong footprint in Germany and Switzerland. PHAST is best known for its finished product testing business, where it serves as a strategic partner to medium and large pharmaceutical companies. PHAST provides pharmaceutical services with a focus on quality control (QC) testing of small and large molecules, and analytical development services. PHAST’s services portfolio comprises attractive high-end capabilities (i.e. Nuclear Magnetic Resonance (NMR), mass spectrometry, inhalation testing). Headquartered in Homburg, Germany, and with additional sites in Constance, Germany, as well as in Switzerland, PHAST operates two state-of-the-art laboratory facilities totaling 6,000 m2, with ample space for expansion.
The acquisition of PHAST will complement Eurofins’ BioPharma Product Testing capabilities and expand Eurofins’ geographical footprint in these markets. The wide array of testing expertise acquired from PHAST will strengthen Eurofins’ BioPharma Product Testing portfolio. Eurofins is well-positioned to capitalize on the strong growth and the positive trends underlying the BioPharma industry, which also increasingly opts for outsourcing laboratory services.
Eurofins is an international group of laboratories headquartered in Brussels, providing testing and support services to the pharmaceutical, food, environmental, agriscience and consumer products industries.